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This review provides an outline of the association between major depressive disorder (MDD) 
and coronary heart disease (CHD). Much is known about the two individual clinical condi-
tions; however, it is not until recently, biological mechanisms have been uncovered that link 
both MDD and CHD. The activation of stress pathways have been implicated as a neuro-
chemical mechanism that links MDD and CHD. Depression is known to be associated with 
poorer outcomes of CHD. Psychological factors, such as major depression and stress, are 
now known as risk factors for developing CHD, which is as important and is independent 
of classic risk factors, such as hypertension, diabetes mellitus, and cigarette smoking. Both 
conditions have great socioeconomic importance given that depression and CHD are likely 
to be two of the three leading causes of global burden of disease. Better understanding of 
the common causal pathways will help us delineate more appropriate treatments.
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The known major links between CHD and MDD are outlined in this review. The search terms 
“depression, major depressive disorder, coronary heart disease, cardiac risk, cardiovascular disease,” 
were entered into an electronic database, “PubMed.” Articles published between 1950 and 2015, and 
written in English were chosen. Abstracts were then hand screened for relevance and were selected 
on the basis of addressing mechanisms associating MDD and CHD.
DePReSSiON AND CORONARY HeART DiSeASe PRevALeNCe
Major depression is a debilitating condition that presents with a number of cognitive and biological 
symptoms, including a pervasively lowered mood, anhedonia, negative cognitions, anergia, and 
appetite disturbance, and at its worst can manifest itself with suicidal thoughts and acts and psychotic 
features (1). The lifetime prevalence rates of major depression are in the order of 17%. It is known 
that major depression is more prevalent in people who have suffered a major cardiac event, with up 
to 40% of patients meeting the criteria for major depressive disorder (MDD) (2). The large European 
Action on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE) study 
showed potentially even higher rates with up to 35% of men and up to 65% of women measured 
as having depression on the hospital anxiety and depression scale (3). The enhancing recovery in 
coronary heart disease (ENRICHD) trial looked at patients who had recently suffered a myocardial 
infarction (MI), and depression was diagnosed in 74% of them (4). If we look at figures from the 
community through to those who are hospitalized, we see rates of depression of 10% in general 
practice clinics (5, 6), which then increases to up to 30% in those with coronary heart disease (CHD) 
in outpatient clinics (5–8), and up to a staggering 50% in those who are an inpatient for coronary 
artery bypass surgery (6, 9).
FiGURe 1 | Possible mechanisms whereby depression confers elevated cardiac risk. This is likely to be multifactorial including sympathetic activation, 
hypothalamic–pituitary activation, endothelial dysfunction, platelet activation, proinflammatory cytokines, and atherosclerosis development along with cardiac 
vascular and rhythm abnormalities.
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The leading cause of mortality in the developed world is 
coronary artery disease (CAD). When cardiac disease and major 
depression present together, the prognosis for both worsen 
(10–12). Reviews have continually shown that major depression 
is associated with poorer quality of life (13) and increased mor-
bidity (14–16) and mortality (7–9, 17, 18). If MDD is present at 
baseline in a CHD patient, then it is an independent risk factor for 
poorer cardiovascular outcomes including MI (16).
A meta-analysis of 11 studies showed that MDD conferred an 
overall relative risk of 1.64 for developing CHD (19). The severity 
of the depression is proportional to the risk of developing CAD 
(20). Regarding mortality, MDD confers a relative risk of 1.8 in 
those suffering comorbid CHD (21). For those who have suffered 
a MI, the presence of MDD is a bad prognostic factor and carries a 
five times increased risk of cardiac mortality within 6 months (22).
MeCHANiSMS OF MAJOR DePReSSiON 
AND iNCReASeD CARDiAC RiSK
It has long been accepted that there are numerous behavioral and 
lifestyle factors at play that confers increased CHD risk in those 
suffering depression. Psychological stress experienced by people 
suffering from MDD can also cause deregulation in the sym-
pathetic nervous system and hypothalamic–pituitary– adrenal 
(HPA) axis (23, 24) (see Figure 1). This in turn has a number 
of deleterious downstream effects, including the development of 
hypertension, left ventricular hypertrophy (25), coronary vaso-
constriction, endothelial dysfunction (26–28), platelet activation, 
and the production of pro inflammatory cytokines (29, 30) (see 
Table 1). The potential consequence of this is an elevated risk in 
ventricular arrhythmias (31) and MI (32).
BeHAviOURAL AND LiFeSTYLe FACTORS
It is well established that there are number of behavioral and lifestyle 
factors, which are present in MDD patients that can increase the 
chance of developing CHD (40). These include increased rates of 
smoking, alcohol intake, physical inactivity, and obesity (33). As seen 
with other medical conditions, major depression predicts poorer 
adherence responses in CHD patient to medications (41), lifestyle 
(42–44), and rehabilitation programs (45). In fact, non-completion 
rates in cardiac rehabilitation have been shown to be in the order of 
44% compared to 29% in the non-depressed group (46). Therefore, 
we are likely to see the depressed CHD patient being less motivated 
and adherent to cardiac rehabilitation programs. MDD also makes 
it less likely to engage in lifestyle modification after a major cardiac 
event to reduce the classic risk factors of CHD. We see this with 
regards to cigarette smoking, where MDD patients are less likely to 
give up smoking and there consumption is also heavier (47).
DiSTURBANCe iN AUTONOMiC NeRvOUS 
SYSTeM
It has long been known that “stress” and heart disease are linked 
(10, 48). Stressful events, such as terrorist attacks (49), natural 
disasters (50), and even high stakes knockout soccer matches, have 
been positively associated with an increase in acute cardiovascular 
events (51). Mental stress is one of the many cognitive symptoms 
that people with major depression suffer from. Laboratory mental 
stress tests have been shown to activate sympathetic nervous 
outflow in the non-cardiac patient setting (52). The cardiac 
sympathetic nerves are preferentially activated by such mental 
stress (11). In animal models and the clinical setting (31, 53), 
TABLe 1 | Summary of main findings in mechanisms of MDD and cardiac risk.
Reference Objective Subjects Methods Results
Stapelberg 
et al. (33)
To identify a model of causal 
mechanisms that link major 
depressive disorder to 
cardiovascular heart disease
– A comprehensive literature review Mechanisms linking MDD and CHD that are often discussed 
in the literature are genetic, behavioral, and immunological.  
As well as coagulation, omega-3 PUFA deficiency and 
vascular endothelial dysfunction. However, rather than 
discussing them separately, these mechanisms should be 
viewed as interdependent networks
Esler et al. 
(23)
To examine the sympathetic 
nervous system function in 
depression
11 depressed 
patients
Tritiated norepinephrine was used to 
observe the rate of norepinephrine 
spill over. Removal of norepinephrine 
from plasma was performed to 
assess the neuronal uptake of 
norepinephrine
Norepinephrine spill over was elevated in 5 of the 11 
patients with depressive illness. Rapid removal phase of 
norepinephrine from plasma corresponded in patients with 
depression, suggesting increased neuronal uptake
8 patients with 
other psychiatric 
diagnosis
17 healthy subjects
Carney et al. 
(34)
To examine whether depressed 
patients with coronary artery 
disease (CAD) have lower heart 
rate variability compared with 
non-depressed CAD patients
19 depressed CAD 
patients
Patients underwent 24-h Holter 
monitoring, with SD of normal-to-
normal intervals were used as the 
primary index of heart rate variability
Heart rate variability was significantly lower in non-depressed 
CAD patients
19 non-depressed 
CAD patients
Spieker et al. 
(28)
To identify the mechanisms 
behind endothelial functioning in 
response to mental stress
23 healthy subjects Nitroglyercin and flow-mediated 
(FMD) induced vasodilation were 
examined pre- and post-stress. 
FMD was also examined during 
stress
Endothelium-dependent vasodilation decreased by half in 
comparison to endothelium-independent vasodilation to 
nitroglyercin which remained unaffected. Intra-arterial infusion 
of norepinephrine for a similar duration of mental stress  
did not hinder FMD
Schlaich 
et al. (35)
To determine possible 
mechanisms leading to 
sympathetic augmentation in 
hypertension
22 hypertensive 
patients
Microneurography and radio tracer 
dilution were used to measure 
regional sympathetic activity
Patients with hypertension demonstrated reduced neuronal 
norepinephrine reuptake, which in turn was associated with 
sympathetic activation in hypertension11 normotensive 
patients
Dinan (36) To review the biological markers 
of depression, specifically 
neuroendocrine disturbances 
and the hypothalamic–pituitary–
adrenal axis (HPA)
– A comprehensive literature review Numerous studies have demonstrated that MDD results from 
activation from the HPA. Other biological markers may be 
secondary to high glucocorticoid levels
Wong et al. 
(37)
To examine centrally 
directed norepinephrine and 
corticotropin-releasing hormone 
(CRH) secretion in medication-
free patients with melancholic 
depression
10 depressed 
patients
Norepinephrine and CRH were 
measured in lumbar cerebrospinal 
fluid every 30 h in addition to plasma 
adrenocorticotropic hormone and 
cortisol secretion
Depressed patients had significantly higher levels of 
norepinephrine and plasma cortisol yet normal levels of CRH. 
There was a negative correlation between plasma cortisol 
and CRH in healthy patients, while there was no relationship 
demonstrated in the depressed group
14 healthy subjects
Barton et al. 
(38)
To assess the significance of the 
sympathetic nervous system in 
the promotion of cardiac risk in 
patients with MDD
39 depressed 
patients
Whole-body cardiac sympathetic 
activity was measured using 
noradrenaline isotope dilution 
methods and sympathetic nerve 
recording techniques
A bimodal distribution for whole body and heart sympathetic 
activity was demonstrated in patients with MDD. This subset 
of MDD patients had significantly high sympathetic activity76 healthy subjects
Ghiadoni 
et al. (27)
To explore whether mental stress 
promotes atherogenesis via 
the impairment of endothelium-
dependent vascular homeostasis 
in preclinical subjects
8 non-insulin-
dependent diabetic 
patients
Response to sublingual glyceryl 
trinitrate and brachial artery flow-
mediated dilation (FMD) were 
measured before and after a mental 
stress test. It was measured again in 
the healthy group, without a stress 
stimuli on a separate occasion
In healthy subjects, mental stress had no effect on the 
response to sublingual glyceryl trinitrate; however, FMD 
significantly reduced after. Without the stress stimuli, FMD 
was unchanged. While the diabetic group had lower FMD 
in comparison to controls, there were no changes following 
the stimuli for both FMD and sublingual glyceryl trinitrate 
responses
10 healthy subjects
Brown et al. 
(6)
To review the associations 
between MDD and CHD and 
address the clinical implications 
for treatment
– A comprehensive literature review While there is no evidence that treatment of depression 
will reduce this effect, it is still important to improve quality 
of life for those with depression through the benefits of 
psychological and pharmaceutical intervention
Poole et al. 
(39)
To review the relationship 
between depression and 
adverse outcomes from acute 
coronary syndrome (ACS) and 
coronary artery bypass graft 
(CABG) surgery patients
– A comprehensive literature review Inflammation is a frequent causal process involved in the 
development of depressive symptoms and for adverse  
cardiac outcomes
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the significance of the activation of cardiac sympathetic cardiac 
fibers has demonstrated disturbances in heart rhythm, leading to 
increased risk of ventricular arrhythmias, decreased blood flow 
(54), left ventricular hypertrophy (25), and MI and sudden death 
(28). It has been shown that in depressed CHD patients, there is an 
elevated resting heart rate, and this also may be due to sympathetic 
hyperactivity in this group of patients (34).
Thus, it is postulated that the lowered removal of noradrenalin 
from the cardiac sympathetic synapse enhances the sympathetic 
stimulation and as a consequence confers CHD risk (38). In fact, it 
has been shown that there is a bimodal distribution of noradrenalin 
spill over in patients with MDD, with approximately one-third of 
patients exhibiting remarkably high levels (38). Interestingly, it has 
been shown that there is an elevated serotonin turnover in MDD 
patients who have not yet been treated with antidepressants, which 
is associated with the short allele of the serotonin transporter (55). 
This short allele has been also associated with increased urinary 
noradrenalin levels and therefore sympathetic over activity (56).
Hypertension is an established risk factor for the development 
of CHD. Up to 90% of patients with heart failure suffer from 
hypertension (28). Essential hypertension is often triggered and 
maintained by mental stress. The processes here include reduced 
uptake of noradrenalin (35) and activation of brain noradrenergic 
pathways and noradrenalin release from the heart. It has been 
demonstrated that there is indeed elevated noradrenalin levels in 
depressed patient’s plasma and cerebrospinal fluid (57). We have 
seen other psychogenic causes of hypertension with the well-known 
phenomenon of white coat hypertension, which persists after 
numerous visits (58), where you would traditionally expect some 
form of desensitization to occur and blood pressures to normalize.
With regards to the parasympathetic system, a further possible 
mechanism linking MDD and CHD includes heart rate variabil-
ity as a marker of vagal activity (59). Decreased heart variability 
(60–62) is associated with post-infarct mortality (63–66). Heart 
rate variability is modulated by the cardiac vagus and has been 
described in MDD patients (10).
DiSTURBANCe OF THe  
HYPOTHALAMiC–PiTUiTARY–ADReNAL 
AXiS
Major depressive disorder has been implicated in the stress-
induced activation of the HPA axis (36). Elevated levels of cor-
tisol have repeatedly been found in MDD patients (37, 67, 68). 
This hypercortisolemia causes an increased risk of a metabolic 
syndrome type state, which includes glucose intolerance, hyper-
lipidemia, and increased visceral fat mass (69–71). This metabolic 
syndrome not only confers a higher risk of cardiovascular disease 
(72) and diabetes (73) but has also been shown to drive sympa-
thetic activation (74).
PLATeLeT, iNFLAMMATORY AND 
AUTOiMMUNe MeCHANiSMS
Stress and anxiety, both common symptoms of major depres-
sion, can contribute to atherosclerosis (38). Increased platelet 
activation and endothelial dysfunction have been implicated 
as a potential pathophysiological pathway linking MDD and 
CHD (75, 76).
Prolonged mental stress, which is commonly experienced in 
those suffering from major depression, has been shown to induce 
prolonged endothelial dysfunction (27, 28). This endothelial 
dysfunction has been shown to be one of the early signs of future 
cardiovascular deterioration (77). In fact, oxidative stress itself 
has been described in numerous psychiatric illnesses (78).
Antiplatelet medication, such as aspirin, has long been a 
mainstay of preventative treatment of CHD (79). As stated, 
depression has been implicated with increased platelet reactivity 
(80), which will increase the relative risk of thrombus forma-
tion and arterial occlusion (10). MDD is associated with raised 
platelet serotonin levels, which promotes clotting (81). Further 
evidence of platelet activation can be shown by elevated levels 
of  beta-thromboglobulin, which are raised in depressed CHD 
patients (80). It is this prothrombotic state, which leads to throm-
bus formation and consequently myocardial ischemia (17).
Inflammatory pathways have been proposed as one of the 
causal pathways responsible for MDD causing increased CHD 
risk (39), via atherosclerosis (82). Depressed patients have been 
found to have elevated levels of inflammatory markers, such as 
C-reactive protein (CRP), and proinflammatory cytokines, such 
as interleukin 1, 2, 6, and tumor necrosis factor (83–87). A num-
ber of these inflammatory markers have also been consistently 
associated with poor cardiovascular outcomes (88), and CRP can 
predict MI (89).
iMPLiCATiONS FOR TReATMeNT
Once major depression is present in those who have had a major 
cardiac event, we can expect them to still be suffering from 
depressive symptoms 4 months post discharge from hospital (90). 
It is important to recognize depression in CHD, yet the major-
ity of cases are not diagnosed or managed accordingly (91). In 
a consensus statement from the National Heart Foundation of 
Australia, they recommended that routine screening for depres-
sion is carried out for all patients suffering from CHD and first 
presentation and at follow-up (92). A perceived barrier to screen-
ing for depression by clinicians is lack of time (93). A quick and 
simple way to screen for depression in this setting would be to use 
a validated rating scale, such as the Cardiac Depression Scale (94).
The onset of a major depression has been shown to negatively 
moderate treatment outcomes for CHD patients (95). A recent 
Cochrane review showed that antidepressant medication was 
superior to placebo in the treatment of major depression in those 
who are also physically unwell.
Of the various antidepressants available to treat MDD, it is not 
known which is the best to lower the risk of CVD events in those 
suffering MDD (96). Common side effects of antidepressants must 
be taken into consideration when prescribing in those depressed 
CHD patients. This includes dizziness, appetite changes, sleep 
disturbance, gastrointestinal side effects, and sexual side effects.
Selective serotonin reuptake inhibitors (SSRIs) are the 
first-line pharmacotherapy for the treatment of major depres-
sion. This is generally because of their tolerability and safety 
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profile (97, 98) and are deemed to be safe in the cardiac setting 
(6, 99). The SSRIs have been shown to have a meaningful effect 
on major depression (100). The Sertraline Antidepressant Heart 
Attack Randomized Trial (SADHART) demonstrated that the 
antidepressant sertraline improved depression in those who had 
suffered acute coronary syndrome (ACS) (101). The safety and 
efficacy of sertraline in the CHD group was evidenced in this 
study (101). The ENRICHD trial showed that antidepressant 
treatment improved CHD prognosis (102). In the review by 
(103), it was shown that antidepressant medication can positively 
alter physiological pathways linking MDD and CHD. We have 
stated that sympathetic over activity is important in causality of 
CHD, and reductions in sympathetic activity have been shown 
following SSRI treatment (104). However, SSRIs are not without 
their flaws, and it has been noted that some induce weight gain 
and metabolic abnormalities (105–109).
There are various classes of antidepressants, such as the 
aforementioned selective SSRIs, tricyclic antidepressants (TCAs), 
and monoamine oxidase inhibitors (MAOIs). They are equally as 
efficacious (110), but differ significantly in their receptor and this 
side effect profiles. The TCAs and MAOIs are generally avoided 
in the treatment of major depression in those who have comorbid 
cardiac conditions, because of their toxic cardiac side effects (111). 
TCAs have been associated with elevated relative risk of 1.24 for 
CHD (112) and increased mortality rates in CHD (113). TCAs are 
also are also highly toxic in overdose (114), which is of concern 
to the prescribing clinician especially when treating those with a 
history of suicidal behavior. TCAs can cause QTc prolongation 
(115) and decrease heart rate variability (64) secondary to their 
anticholinergic effects.
With regards to psychological therapies for depression, such as 
cognitive behavioral therapy (CBT), they seem to be efficacious 
for the depression without being beneficial for CHD morbidity or 
mortality (116). The UK National Institute of Clinical Excellence’s 
(NICE) guideline on depression in adults with chronic physical 
health problems advises that psychological treatment (such as 
CBT) be the first line of treatment for mild to moderate depres-
sion (110). However, this may not hold true for CHD patients 
and certainly is not the case for those suffering a more moderate 
to severe form of major depression, where biological treatment, 
such as antidepressants, are favored.
Physical exercise has long thought to be beneficial for one’s 
mental state, and in the past, it was common to see exercise 
prescribed by their doctors, to aid with the treatment of major 
depression. A Cochrane review has indicated that moderate 
aerobic exercise in the order of 30  min, five times a week is 
beneficial for relieving MDD symptoms. The magnitude of its 
efficacy should not be dismissed as Cochrane showed it had 
similar efficacy to CBT (117), and it of course will be beneficial 
to one’s cardiovascular health. In those who exercise, it can be 
seen that depression, quality of life, and global functioning scores 
improve, thus decreasing the intensity and longevity of the epi-
sode of MDD (118). In the cardiac rehabilitation, setting exercise 
programs has not only shown to be beneficial for depression 
scores but also improves body percentage fat, triglyceride, and 
cholesterol levels (119).
In relation to platelet function, we have already discussed 
that platelet hyperactivity leads to a prothrombotic state, which 
in turn leads to increased risk of CHD. The SADHART platelet 
substudy showed a decreased platelet activation in those patients 
who had suffered an MI, were depressed, and had it treated with a 
SSRI, namely, sertraline (101). Paroxetine has also been shown to 
decrease platelet hyperactivity (120, 121). SSRIs have been shown 
to decrease sympathetic hyperactivity and, as a consequence, 
potentially reduce cardiac morbidity and mortality (38).
CONCLUSiON
The underlying mechanism linking MDD and CHD are com-
plex and multifactorial. As discussed, they involve the sym-
pathetic nervous system, platelet hyperactivity, inflammation, 
and HPA dysregulation among others. Given that a definitive 
mortality study is unlikely to be done due to the complexities 
and costs involved, we are therefore guided by current evidence 
to maximize efficacy and potential harm when choosing our 
treatments for MDD who have comorbid CHD. We should be 
considering MDD as a common and modifiable risk factor for 
CHD, just like we do for smoking, hypertension, hyperlipi-
demia, and the like. The toxic combination of MDD and CHD 
leads to poorer health outcomes for both conditions and esca-
lating health-care costs. The implications for research is that 
further understanding of the pathophysiological mechanisms 
underpinning MDD and CHD is required so as to inform us 
of better treatments. It would be interesting to see not only 
studies looking at underlying biological mechanisms but also 
clinical ones. There needs to be an effort to try and minimize 
the barriers to screening and treating of MDD in those suffer-
ing from CHD. Given the bidirectionality of the conditions, it 
would also be useful to elucidate whether treatments for CHD 
can potentially decrease the intensity of symptom burden of 
MDD. Future clinical practice may include initiating cardio-
protective medications alongside antidepressants when MDD 
is diagnosed, thus alleviating the morbidity, mortality, and cost 
burdens of MDD and CHD.
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